<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN"
        "https://jats.nlm.nih.gov/publishing/1.4/JATS-journalpublishing1-4.dtd">
<article  article-type="reviewer-report"        dtd-version="1.4">
            <front>

                <journal-meta>
                                                                <journal-id>jonn</journal-id>
            <journal-title-group>
                                                                                    <journal-title>Nefroloji Hemşireliği Dergisi</journal-title>
            </journal-title-group>
                                        <issn pub-type="epub">2147-7728</issn>
                                                                                            <publisher>
                    <publisher-name>Türk Nefroloji, Diyaliz ve Transplantasyon Hemşireleri Derneği</publisher-name>
                </publisher>
                    </journal-meta>
                <article-meta>
                                        <article-id pub-id-type="doi">10.47565/ndthdt.2023.66</article-id>
                                                                <article-categories>
                                            <subj-group  xml:lang="en">
                                                            <subject>Nursing</subject>
                                                    </subj-group>
                                            <subj-group  xml:lang="tr">
                                                            <subject>Hemşirelik</subject>
                                                    </subj-group>
                                    </article-categories>
                                                                                                                                                        <title-group>
                                                                                                                        <article-title>Böbrek Kanseri ve Hemşirelik Yönetimi/ Kidney Cancer and Nursing Management</article-title>
                                                                                                                                                                                                <trans-title-group xml:lang="en">
                                    <trans-title>Kidney Cancer and Nursing Management/ Böbrek Kanseri ve Hemşirelik Yönetimi</trans-title>
                                </trans-title-group>
                                                                                                    </title-group>
            
                                                    <contrib-group content-type="authors">
                                                                        <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0001-8817-0511</contrib-id>
                                                                <name>
                                    <surname>Kavala</surname>
                                    <given-names>Arzu</given-names>
                                </name>
                                                                    <aff>İSTANBUL AYDIN ÜNİVERSİTESİ</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0002-6228-0007</contrib-id>
                                                                <name>
                                    <surname>Yıldırım</surname>
                                    <given-names>Dilek</given-names>
                                </name>
                                                                    <aff>İSTANBUL AYDIN ÜNİVERSİTESİ</aff>
                                                            </contrib>
                                                                                </contrib-group>
                        
                                        <pub-date pub-type="pub" iso-8601-date="20230131">
                    <day>01</day>
                    <month>31</month>
                    <year>2023</year>
                </pub-date>
                                        <volume>18</volume>
                                        <issue>1</issue>
                                        <fpage>37</fpage>
                                        <lpage>44</lpage>
                        
                        <history>
                                    <date date-type="received" iso-8601-date="20220907">
                        <day>09</day>
                        <month>07</month>
                        <year>2022</year>
                    </date>
                                                    <date date-type="accepted" iso-8601-date="20221012">
                        <day>10</day>
                        <month>12</month>
                        <year>2022</year>
                    </date>
                            </history>
                                        <permissions>
                    <copyright-statement>Copyright © 2004, Journal of Nephrology Nursing</copyright-statement>
                    <copyright-year>2004</copyright-year>
                    <copyright-holder>Journal of Nephrology Nursing</copyright-holder>
                </permissions>
            
                                                                                                <abstract><p>Dünyada ve ülkemizde önemli toplumsal sağlık sorunlarından biri olan kanser kardiyovasküler hastalıklardan sonra ikinci ölüm nedeni olarak görülmektedir. Her geçen gün artış gösteren kanserin 2030 yılına kadar birinci sıraya yerleşeceği düşünülmektedir. Böbrek kanseri prostat ve mesane kanserinden sonra en sık görülen ürogenital kanserdir. Genetik değişiklikleri olan, farklı klinik seyirlerle ilerleyen ve tedaviye farklı yanıtları olan birkaç farklı kanser türünü temsil etmektedir. Böbrek kanserlerinin yarısından fazlası tesadüfen keşfedilmekte ve kilo kaybı, iştahsızlık, anoreksi, öksürük, kemik ağrısı, hematüri, yorgunluk, vücut ısısında artış gibi belirti ve bulgular gözlemlenmektedir. Böbrek kanserlerinin tanısında yer alan yan ağrısı, hematüri ve kitle ise hastaların çok azında gözlemlenmektedir. Böbrek kanserinin tedavisinde cerrahi tedavi, laparoskopik yöntemlerle yapılan nefron koruyucu cerrahi yöntemleri, hedefe yönelik tedaviler, immünoterapi ve semptom yönetimi tercih edilmektedir. Tüm bu tedavi süreçlerinde hastaların ve hasta yakınlarının hemşirelik bakımına ihtiyaçları vardır. Hemşirelik bakımının amacı; tedavi öncesi değerlendirmenin sağlanması, tedavi süreci, tedavi sonrasındaki bakımın verilmesi, hasta ve yakınlarının eğitimlerinin planlanması ve gerçekleştirilmesini kapsamaktadır. Hemşirelerin, hasta ve hasta yakınlarına eğitim vermesi sağlık bilincini arttırmada önemli bir yere sahiptir. Bu nedenle bu derlemede böbrek kanserli hastaların komplikasyonlarını önlemede, tedavide ve eğitimde hemşirelik yönetiminin öneminin vurgulanması ve hemşirelerin bu konuda farkındalıklarının arttırılması amaçlanmaktadır.</p></abstract>
                                                                                                                                    <trans-abstract xml:lang="en">
                            <p>Cancer, which is one of the important social health problems in the world and in our country, is seen as the second cause of death after cardiovascular diseases. It is thought that cancer, which is increasing day by day, will rank first by 2030. Kidney cancer is the most common urogenital cancer after prostate and bladder cancer. It represents several different types of cancer with genetic changes, progressing with different clinical courses, and different responses to treatment. More than half of kidney cancers are discovered by chance, and signs and symptoms such as weight loss, loss of appetite, anorexia, cough, bone pain, hematuria, fatigue, and an increase in body temperature are observed. Flank pain, hematuria, and mass, which are included in the diagnosis of kidney cancers, are observed in very few of the patients. Surgical treatment, nephron-sparing surgery methods performed with laparoscopic methods, targeted therapies, immunotherapy, and symptom management are preferred in the treatment of kidney cancer. In all these treatment processes, patients and their relatives need nursing care. The purpose of nursing care: It includes providing pre-treatment evaluation, treatment process, post-treatment care, planning, and realization of education of patients and their relatives. Nurses&#039; training for patients and their relatives have an important place in raising health awareness. Therefore, in this review, it is aimed to emphasize the importance of nursing management in preventing complications of patients with kidney cancer, in treatment and education, and to increase the awareness of nurses on this issue.</p></trans-abstract>
                                                            
            
                                                            <kwd-group>
                                                    <kwd>Böbrek kanseri</kwd>
                                                    <kwd>  hemşirelik bakımı</kwd>
                                                    <kwd>  hemşirelik yönetimi</kwd>
                                            </kwd-group>
                                                        
                                                                            <kwd-group xml:lang="en">
                                                    <kwd>kidney cancer</kwd>
                                                    <kwd>  nursing care</kwd>
                                                    <kwd>  nursing management</kwd>
                                            </kwd-group>
                                                                                                            </article-meta>
    </front>
    <back>
                            <ref-list>
                                    <ref id="ref1">
                        <label>1</label>
                        <mixed-citation publication-type="journal">1. Türkiye Kanser İstatistikleri. T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu. 2017. www.kanser.gov.tr/dairefaaliyetleri/kanser-istatistikleri.html. Erişim tarihi: 12.08.2022.</mixed-citation>
                    </ref>
                                    <ref id="ref2">
                        <label>2</label>
                        <mixed-citation publication-type="journal">2. Ayoğlu T, Özbaş A. Böbrek Kanser. Can G. (ed.) Onkoloji Hemşireliği. Nobel Tıp Kitapevi. 2015. s: 719-29.</mixed-citation>
                    </ref>
                                    <ref id="ref3">
                        <label>3</label>
                        <mixed-citation publication-type="journal">3. Cancer Key facts 03 March 2021. WHO. https://www.who.int/en/news-room/fact-sheets/detail/cancer. Erişim tarihi:12.08.2022.</mixed-citation>
                    </ref>
                                    <ref id="ref4">
                        <label>4</label>
                        <mixed-citation publication-type="journal">4. TÜİK. Ölüm Nedeni İstatistikleri. 2017. tuikweb.tuik.gov.tr/ Pre Haber Bultenleri. Erişim tarihi: 12.08.2022.</mixed-citation>
                    </ref>
                                    <ref id="ref5">
                        <label>5</label>
                        <mixed-citation publication-type="journal">5. Linehan WM, Schmidt LS, Crooks DR, Wei D, Srinivasan R, Lang M, et al. The Metabolic Basis of Kidney Cancer. Cancer
Discov. 2019;9(8):1006-21. DOI: 10.1158/2159-8290.CD-18-1354.</mixed-citation>
                    </ref>
                                    <ref id="ref6">
                        <label>6</label>
                        <mixed-citation publication-type="journal">6. Kidney Cancer Stages. https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/staging.html. Erişim tarihi:
15.08.2022.</mixed-citation>
                    </ref>
                                    <ref id="ref7">
                        <label>7</label>
                        <mixed-citation publication-type="journal">7. Patel P and Srinivas S. Epidemiology of Renal Cell Carcinoma. Lara P, Jonasch E. (ed.). Kidney Cancer Principles and Practice.
Springer Heidelberg Dordrecht London New York.2012. s:3-17.</mixed-citation>
                    </ref>
                                    <ref id="ref8">
                        <label>8</label>
                        <mixed-citation publication-type="journal">8. Cinque A, Vago R, Trevisani F. Circulating RNA in Kidney Cancer: What we know and what we still suppose. Genes (Basel).
2021.28;12(6):835. doi: 10.3390/genes12060835.</mixed-citation>
                    </ref>
                                    <ref id="ref9">
                        <label>9</label>
                        <mixed-citation publication-type="journal">9. Lekili M. Böbrek tümörleri için tarama programları var mı? Gerekir mi? Üroonkoloji Bülteni. 2010;(3):37-39.</mixed-citation>
                    </ref>
                                    <ref id="ref10">
                        <label>10</label>
                        <mixed-citation publication-type="journal">10. You D, Choi SY, Ryu J, Kim C. Surgical Consideration in Renal Tumors. Mukul K. Divatia MK, Ozcan A, Guo CC, Ro JY.
(ed.). Kidney Cancer. Springer Nature Switzerland AG 2020. ISBN 978-3-030-28333-9 (eBook). DOI:10.1007/978-3-030-
28333-9. s:3-21.</mixed-citation>
                    </ref>
                                    <ref id="ref11">
                        <label>11</label>
                        <mixed-citation publication-type="journal">11. Sinibaldi VJ, Pratz CF, Yankulina O. Kidney cancer: toxicity management, symptom control and palliative care. J Clin
Oncology. 2018; 36:3632-38.</mixed-citation>
                    </ref>
                                    <ref id="ref12">
                        <label>12</label>
                        <mixed-citation publication-type="journal">12. Moldawer NP, Wood LS. The critical role of the oncology nurse as a partner in the management of patients with advanced
kidney cancer: toxicity management, symptom control and palliative care. Cancer J. 2020;26(5):460-3. DOI:
10.1097/PPO.0000000000000476.</mixed-citation>
                    </ref>
                                    <ref id="ref13">
                        <label>13</label>
                        <mixed-citation publication-type="journal">13. O&#039;Dea A, Gedye C, Jago B, Paterson C. Identifying the unmet supportive care needs of people affected by kidney cancer: a
systematic review. J Cancer Surviv. 2021 (1):1-17. DOI: 10.1007/s11764-021-01113-8.</mixed-citation>
                    </ref>
                                    <ref id="ref14">
                        <label>14</label>
                        <mixed-citation publication-type="journal">14. Chowdhury N, Drake CG. Kidney cancer: an overview of current therapeutic approaches. Urol Clin North Am. 2020;47(4):419-
431. DOI: 10.1016/j.ucl.2020.07.009.</mixed-citation>
                    </ref>
                                    <ref id="ref15">
                        <label>15</label>
                        <mixed-citation publication-type="journal">15. Géczi L, Nagyiványi K, Maráz A. Immunterápia a vesedaganatok kezelésében [Immunotherapy of renal cell cancer]. Magy
Onkol. 2017;61(2):126-131.</mixed-citation>
                    </ref>
                                    <ref id="ref16">
                        <label>16</label>
                        <mixed-citation publication-type="journal">16. Santoni M, Massari F, Di Nunno V, Conti A, Cimadamore A, Scarpelli M, et al. Immunotherapy in renal cell carcinoma: latest
evidence and clinical implications. Drugs in Context 2018;7: DOI: 10.7573/dic.212528.</mixed-citation>
                    </ref>
                                    <ref id="ref17">
                        <label>17</label>
                        <mixed-citation publication-type="journal">17. Renal Cell Cancer Treatment–Patient Version. https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq. (Erişim
Tarihi: 01.09.2022).</mixed-citation>
                    </ref>
                                    <ref id="ref18">
                        <label>18</label>
                        <mixed-citation publication-type="journal">18. Cosmai L, Pirovano M, Re Sartò GV, Gallieni MA. Immunotherapy in kidney cancer: how it has changed and what are the
challenges for the nephrologist - focus on pembrolizumab. G Ital Nefrol. 2021 ;38(5):2021-vol5.</mixed-citation>
                    </ref>
                                    <ref id="ref19">
                        <label>19</label>
                        <mixed-citation publication-type="journal">19. Hammers H. Immunotherapy in kidney cancer: the past, present, and future. Curr Opin Urol. 2016 Nov;26(6):543-7. DOI:
10.1097/MOU.0000000000000338.</mixed-citation>
                    </ref>
                                    <ref id="ref20">
                        <label>20</label>
                        <mixed-citation publication-type="journal">20. Carlo MI, Voss MH, Motzer RJ. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nat
Rev Urol. 2016;13(7):420-31. DOI: 10.1038/nrurol.2016.103.</mixed-citation>
                    </ref>
                                    <ref id="ref21">
                        <label>21</label>
                        <mixed-citation publication-type="journal">21. Hasanov E, Gao J, Tannir NM. The immunotherapy revolution in kidney cancer treatment: scientific rationale and firstgeneration results. Cancer J. 2020;26(5):419-431. DOI: 10.1097/PPO.0000000000000471.</mixed-citation>
                    </ref>
                                    <ref id="ref22">
                        <label>22</label>
                        <mixed-citation publication-type="journal">22. Martini A, Fallara G, Pellegrino F, Cirulli GO, Larcher A, Necchi A, et al. Neoadjuvant and adjuvant immunotherapy in renal
cell carcinoma. World J Urol. 2021;39(5):1369-76. DOI: 10.1007/s00345-020-03550-z.</mixed-citation>
                    </ref>
                                    <ref id="ref23">
                        <label>23</label>
                        <mixed-citation publication-type="journal">23. Linehan WM, Rathmell WK. Kidney cancer. Urol Oncol. 2012;30(6):948-51. DOI: 10.1016/j.urolonc.2012.08.021.</mixed-citation>
                    </ref>
                                    <ref id="ref24">
                        <label>24</label>
                        <mixed-citation publication-type="journal">24. Deleuze A, Saout J, Dugay F, Peyronnet B, Mathieu R, Verhoest G, et al. Immunotherapy in renal cell carcinoma: the future ıs
now. Int J Mol Sci. 2020 5;21(7):2532. DOI: 10.3390/ijms21072532.</mixed-citation>
                    </ref>
                                    <ref id="ref25">
                        <label>25</label>
                        <mixed-citation publication-type="journal">25. Francisco ALM, Macía M, Alonso F, García P, Gutierrez E, Quintana LF, et al. Onco-Nephrology: Cancer, chemotherapy and
kidney. Nefrologia (Engl Ed). 2019;39(5):473-481. DOI: 10.1016/j.nefro.2018.10.016.</mixed-citation>
                    </ref>
                                    <ref id="ref26">
                        <label>26</label>
                        <mixed-citation publication-type="journal">26. Can G. Onkolojik Hastalıklar ve Hemşirelik Bakımı. N. Enç (Ed), İç Hastalıkları Hemşireliği içinde, Genişletilmiş ve
Güncellenmiş 3. Baskı, İstanbul, Nobel Tıp Kitabevleri. 2021. s: 368-99.</mixed-citation>
                    </ref>
                                    <ref id="ref27">
                        <label>27</label>
                        <mixed-citation publication-type="journal">27. Thompson RM, Patel CR: palliative care principles primary care physicians should know. Primary Care Reports.2013(1).</mixed-citation>
                    </ref>
                                    <ref id="ref28">
                        <label>28</label>
                        <mixed-citation publication-type="journal">28. Salins N, Ramanjulu R, Patra L, et al: Integration of early specialist palliative care in cancer care and patient related outcomes:
A critical review of evidence. Indian J Palliat Care. 2016;22:252-7</mixed-citation>
                    </ref>
                                    <ref id="ref29">
                        <label>29</label>
                        <mixed-citation publication-type="journal">29. Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, Basch EM, et al. Integration of palliative care into standard oncology
care: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol.2017; 35:96-112.</mixed-citation>
                    </ref>
                                    <ref id="ref30">
                        <label>30</label>
                        <mixed-citation publication-type="journal">30. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al: Early palliative care for patients with
metastatic nonsmall- cell lung cancer. N Engl J Med. 2010;363:733-742,</mixed-citation>
                    </ref>
                            </ref-list>
                    </back>
    </article>
